

# Stephane Chauvie

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9285611/publications.pdf>

Version: 2024-02-01

98  
papers

27,260  
citations

304743

22  
h-index

106344

65  
g-index

99  
all docs

99  
docs citations

99  
times ranked

20926  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with Râ€CHOP14: A SAKK 38/07 trial postâ€hoc analysis. <i>Hematological Oncology</i> , 2022, 40, 12-22.   | 1.7 | 13        |
| 2  | Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 729-739.  | 1.6 | 34        |
| 3  | A prognostic model integrating PETâ€derived metrics and image texture analyses with clinical risk factors from GOYA. <i>EJHaem</i> , 2022, 3, 406-414.   | 1.0 | 6         |
| 4  | The role of medical physicists in clinical trials across Europe. <i>Physica Medica</i> , 2022, 100, 31-38.   | 0.7 | 2         |
| 5  | Standardization of <sup>18</sup> F-FDGâ€PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 116-125.  | 1.6 | 85        |
| 6  | Random survival forest to predict transplant-eligible newly diagnosed multiple myeloma outcome including FDG-PET radiomics: a combined analysis of two independent prospective European trials. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1005-1015. | 6.4 | 35        |
| 7  | CualificaciÃ³n de fantasmas 18F para ensayos clÃnicos con imagen PET/TC-18F-FDG adoptada por GELTAMO (Grupo EspaÃol de Linfomas/Trasplante AutÃlogo de MÃdula Ãsea). <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2021, 40, 149-154.                                 | 0.0 | 0         |
| 8  | The 18â€F phantom clinical trials qualification for 18F-FDG-PET scanning adopted by GELTAMO (Grupo Tj ETQq0 0 0 rgBT /Overlock 10 Imagen Molecular, 2021, 40, 149-154.   | 0.2 | 2         |
| 9  | Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi. <i>Annals of Hematology</i> , 2021, 100, 2547-2556.  | 1.8 | 1         |
| 10 | Myocardial Metabolic Response Predicts Chemotherapy Curative Potential on Hodgkin Lymphoma: A Proof-of-Concept Study. <i>Biomedicines</i> , 2021, 9, 971.  | 3.2 | 1         |
| 11 | Lesion Dissemination in Baseline PET/CT (D-MAX) and IPS Score Predict ABVD Treatment Outcome in PET-2 Negative Advanced-Stage Hodgkin Lymphoma Patients Enrolled in the Prospective GITIL/FIL HD0607 Trial. <i>Blood</i> , 2021, 138, 2443-2443.   | 1.4 | 3         |
| 12 | The neutrophil to lymphocyte ratio (NLR) and the presence of large nodal mass are independent predictors of early response: A subanalysis of the prospective phase II PETâ€adapted HD0607 trial. <i>Cancer Medicine</i> , 2020, 9, 8735-8746.  | 2.8 | 10        |
| 13 | Consolidation Radiotherapy Could Be Safely Omitted in Advanced Hodgkin Lymphoma With Large Nodal Mass in Complete Metabolic Response After ABVD: Final Analysis of the Randomized GITIL/FIL HD0607 Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 3905-3913.                     | 1.6 | 36        |
| 14 | Artificial intelligence and radiomics enhance the positive predictive value of digital chest tomosynthesis for lung cancer detection within SOS clinical trial. <i>European Radiology</i> , 2020, 30, 4134-4140.   | 4.5 | 17        |
| 15 | The impact of time-of-flight, resolution recovery, and noise modelling in reconstruction algorithms in non-solid-state detectors PET/CT scanners: â€ multi-centric comparison of activity recovery in a 68Ge phantom. <i>Physica Medica</i> , 2020, 75, 85-91.                           | 0.7 | 3         |
| 16 | Learned Deep Radiomics for Survival Analysis with Attention. <i>Lecture Notes in Computer Science</i> , 2020, , 35-45.   | 1.3 | 1         |
| 17 | Monitoring response in lymphomas: qualitative, quantitative, or what else?. <i>Leukemia and Lymphoma</i> , 2019, 60, 302-308.  | 1.3 | 5         |
| 18 | CONSOLIDATION RADIOTHERAPY COULD BE OMITTED IN ADVANCED HODGKIN LYMPHOMA WITH LARGE NODAL MASS IN COMPLETE METABOLIC RESPONSE AFTER ABVD. FINAL ANALYSIS OF THE RANDOMIZED HD0607 TRIAL. <i>Hematological Oncology</i> , 2019, 37, 147-148.  | 1.7 | 3         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | RADIOMICS INCREASE THE PROGNOSTIC VALUE OF CLINICAL AND PET RISK FACTORS IN DLBCL: RESULTS FROM THE PHASE 3 GOYA STUDY. <i>Hematological Oncology</i> , 2019, 37, 52-53.  | 1.7 | 0         |
| 20 | The role of PET/CT in the modern treatment of Hodgkin lymphoma. <i>Cancer Treatment Reviews</i> , 2019, 77, 44-56.  | 7.7 | 51        |
| 21 | RESPONSE ORIENTED MAINTENANCE THERAPY IN ADVANCED FOLLICULAR LYMPHOMA. RESULTS OF THE INTERIM ANALYSIS OF THE FOLL12 TRIAL CONDUCTED BY THE FONDAZIONE ITALIANA LINFOMI.. <i>Hematological Oncology</i> , 2019, 37, 153-154.                  | 1.7 | 19        |
| 22 | INTERIM ANALYSIS OF CENTRAL REVIEW OF END-OF-THERAPY PET IN FOLL12 TRIAL FOR FOLLICULAR LYMPHOMA. <i>Hematological Oncology</i> , 2019, 37, 393-393.  | 1.7 | 1         |
| 23 | PS1237 DOSE DENSE ABVD (DD-ABVD) AS FIRST LINE THERAPY IN EARLY-STAGE UNFAVOURABLE HODGKIN LYMPHOMA (CHL): RESULTS OF A PHASE II, PROSPECTIVE, MULTI-CENTER STUDY BY FONDAZIONE ITALIANA LINFOMI. <i>HemaSphere</i> , 2019, 3, 563-564.       | 2.7 | 0         |
| 24 | DOSE DENSE ABVD (DD-ABVD) AS FIRST LINE THERAPY IN EARLY-STAGE UNFAVORABLE HODGKIN LYMPHOMA (HD): RESULTS OF A PHASE II, PROSPECTIVE STUDY BY FONDAZIONE ITALIANA LINFOMI. <i>Hematological Oncology</i> , 2019, 37, 291-292.                 | 1.7 | 2         |
| 25 | PET-Derived Quantitative Metrics for Response and Prognosis in Lymphoma. <i>PET Clinics</i> , 2019, 14, 317-329.  | 3.0 | 16        |
| 26 | A core laboratory approach to large-scale radiomics and machine-learning prediction of DLBCL outcomes after first-line treatment using results from the phase III GOYA study.. <i>Journal of Clinical Oncology</i> , 2019, 37, e19042-e19042. | 1.6 | 0         |
| 27 | A Prognostic Model Integrating PET-Derived Quantitative Parameters and Image Texture Analyses Using Radiomics in a Large Prospective Phase III Trial, GOYA. <i>Blood</i> , 2019, 134, 883-883.  | 1.4 | 1         |
| 28 | Dual-point FDG-PET/CT for treatment response assessment in Hodgkin lymphoma, when an FDG-avid lesion persists after treatment. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 9, 176-184.                          | 1.0 | 5         |
| 29 | Is there an optimal method for measuring baseline metabolic tumor volume in diffuse large B cell lymphoma?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1463-1464.  | 6.4 | 19        |
| 30 | Automatic liver detection and standardised uptake value evaluation in whole-body Positron Emission Tomography/Computed Tomography scans. <i>Computer Methods and Programs in Biomedicine</i> , 2018, 156, 47-52.                              | 4.7 | 5         |
| 31 | Interpretation criteria for FDG PET/CT in multiple myeloma (IMPETUs): final results. <i>IMPETUs (Italian) Tj ETQq1 1 0.784314 rgBT /Over</i> 712-719.   | 6.4 | 95        |
| 32 | Metabolic Tumor Volume Metrics in Lymphoma. <i>Seminars in Nuclear Medicine</i> , 2018, 48, 50-66.  | 4.6 | 75        |
| 33 | 280. VATS (Video Assisted Thoracoscopic Surgery) with radiological guidance in hybrid operating room: Technique standardization, organizational aspects and dose optimization. <i>Physica Medica</i> , 2018, 56, 233-234.                     | 0.7 | 0         |
| 34 | 356. ZeroDose: An automatic tool for exposure indexes retrieval from images stored in PACS system. <i>Physica Medica</i> , 2018, 56, 275-276.   | 0.7 | 0         |
| 35 | [OA143] Application of new algorithms in PET image reconstruction: Preliminary results. <i>Physica Medica</i> , 2018, 52, 54-55.  | 0.7 | 0         |
| 36 | 326. PET scanner qualification for clinical trial: Comparison between Italian and worldwide experience. <i>Physica Medica</i> , 2018, 56, 260.  | 0.7 | 0         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Abstract ID: 375 Quantitative imaging in nuclear medicine. <i>Physica Medica</i> , 2018, 56, 284.  | 0.7 | 0         |
| 38 | Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 454-462. | 1.6 | 169       |
| 39 | 281. Prostate artery embolization of benign prostate hyperplasia: Technical and dosimetric aspects. <i>Physica Medica</i> , 2018, 56, 234.   | 0.7 | 0         |
| 40 | 241. Radiation risk due to medical imaging in long living patients: the case of Hodgkin lymphoma. <i>Physica Medica</i> , 2018, 56, 210-211.   | 0.7 | 0         |
| 41 | Standardization of 18F-FDG PET/CT According to Deauville Criteria for MRD Evaluation in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Joined Analysis of Two Prospective Randomized Phase III Trials. <i>Blood</i> , 2018, 132, 257-257.  | 1.4 | 20        |
| 42 | Comparison of digital tomosynthesis and computed tomography for lung nodule detection in SOS screening program. <i>Radiologia Medica</i> , 2017, 122, 568-574.   | 7.7 | 8         |
| 43 | Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1622-1635.  | 6.4 | 91        |
| 44 | Training improves the interobserver agreement of the expert positron emission tomography review panel in primary mediastinal B-cell lymphoma: interim analysis in the ongoing International Extranodal Lymphoma Study Groupâ€³7 study. <i>Hematological Oncology</i> , 2017, 35, 548-553.                                  | 1.7 | 22        |
| 45 | The predictive role of interim PET after the first chemotherapy cycle and sequential evaluation of response to ABVD in Hodgkinâ€™s lymphoma patientsâ€™the Polish Lymphoma Research Group (PLRG) Observational Study. <i>Annals of Oncology</i> , 2017, 28, 3051-3057.   | 1.2 | 16        |
| 46 | Concomitant semi-quantitative and visual analysis improves the predictive value on treatment outcome of interim 18F-fluorodeoxyglucose / Positron Emission Tomography in advanced Hodgkin lymphoma. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, , .   | 0.7 | 3         |
| 47 | The Strategies to Homogenize PET/CT Metrics: The Case of Onco-Haematological Clinical Trials. <i>Biomedicines</i> , 2016, 4, 26.   | 3.2 | 8         |
| 48 | Recent developments in Geant4. <i>Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment</i> , 2016, 835, 186-225.  | 1.6 | 2,327     |
| 49 | The 68 Ge phantom-based FDG-PET site qualification program for clinical trials adopted by FIL (Italian) Tj ETQq1 1 0,784314 rgBT /Ove  | 0.7 | 20        |
| 50 | Brentuximab vedotin followed by ABVD +/â€³ radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study. <i>Haematologica</i> , 2016, 101, e139-e141.  | 3.5 | 12        |
| 51 | 18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease. <i>Leukemia</i> , 2016, 30, 417-422.  | 7.2 | 120       |
| 52 | Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 414-421.  | 6.4 | 92        |
| 53 | PET-Derived Metabolic Volume Metrics in the Hodgkin Lymphoma. , 2016, , 65-98.   |     | 0         |
| 54 | Prospective Evaluation of 18F-FDG PET/CT As Predictor of Prognosis in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients: Results from the Imaging Sus-Study of the EMN02/HO95 MM Randomized Phase III Trial. <i>Blood</i> , 2016, 128, 992-992.   | 1.4 | 0         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease. <i>Leukemia</i> , 2015, 29, 1360-1365.  | 7.2 | 57        |
| 56 | PET-derived metabolic volume metrics in lymphoma. <i>Clinical and Translational Imaging</i> , 2015, 3, 331-341.   | 2.1 | 5         |
| 57 | The Prognostic Role of Interim PET after First Chemotherapy Cycle and PET Sequential Evaluation of Response to ABVD in Hodgkin Lymphoma Patients - the Polish Lymphoma Research Group (PLRG) Observational Study. <i>Blood</i> , 2015, 126, 3943-3943.                | 1.4 | 5         |
| 58 | Role of 123I-Iobenguane Myocardial Scintigraphy in Predicting Short-term Left Ventricular Functional Recovery: An Interesting Image. <i>Journal of Clinical Imaging Science</i> , 2015, 5, 56.  | 1.1 | 0         |
| 59 | The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. <i>Haematologica</i> , 2014, 99, 1107-1113.                                      | 3.5 | 225       |
| 60 | <sup>18</sup> Fluorine-fluorodeoxyglucose positron emission tomography/computed tomography total glycolytic volume in thymic epithelial neoplasms evaluation: a reproducible image biomarker. <i>General Thoracic and Cardiovascular Surgery</i> , 2014, 62, 228-233. | 0.9 | 6         |
| 61 | WIDEN: A tool for medical image management in multicenter clinical trials. <i>Clinical Trials</i> , 2014, 11, 355-361.  | 1.6 | 22        |
| 62 | Brentuximab Vedotin Followed By ABVD in Patients with Previously Untreated Hodgkin Lymphoma. a Pilot Phase II Study. <i>Blood</i> , 2014, 124, 3088-3088.   | 1.4 | 3         |
| 63 | A pilot phase II study with brentuximab vedotin followed by ABVD in patients with previously untreated Hodgkin lymphoma: A preliminary report.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8507-8507.  | 1.6 | 5         |
| 64 | International Validation Study for Interim PET in ABVD-Treated, Advanced-Stage Hodgkin Lymphoma: Interpretation Criteria and Concordance Rate Among Reviewers. <i>Journal of Nuclear Medicine</i> , 2013, 54, 683-690.  | 5.0 | 267       |
| 65 | â€˜ICD in Primary Prevention: Potential Role of Sympathetic Nerve Imagingâ€™™. <i>The Open Cardiovascular Imaging Journal</i> , 2013, 4, 1-3.   | 0.3 | 0         |
| 66 | On-demand lung CT analysis with the M5L-CAD via the WIDEN front-end web interface and an OpenNebula-based cloud back-end. , 2012, , .   |     | 1         |
| 67 | A method for the visual analysis of earlyâ€™stage Parkinson's disease based on virtual MRIâ€™derived SPECT images. <i>International Journal of Imaging Systems and Technology</i> , 2012, 22, 172-176.  | 4.1 | 2         |
| 68 | Early Treatment Intensification in Advanced-Stage High-Risk Hodgkin Lymphoma (HL) Patients, with a Positive FDG-PET Scan After Two ABVD Courses â€™ First Interim Analysis of the GITIL/FIL HD0607 Clinical Trial. <i>Blood</i> , 2012, 120, 550-550.                 | 1.4 | 8         |
| 69 | Dual-point FDG-PET: A novel scanning technique in Hodgkin lymphoma with bulky disease.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8077-8077.  | 1.6 | 2         |
| 70 | WIDEN: A tool for medical imaging management in oncology clinical trials.. <i>Journal of Clinical Oncology</i> , 2012, 30, e13093-e13093.   | 1.6 | 0         |
| 71 | Early chemotherapy intensification with BEACOPP in advancedâ€™stage Hodgkin lymphoma patients with a interimâ€™PET positive after two ABVD courses. <i>British Journal of Haematology</i> , 2011, 152, 551-560.   | 2.5 | 127       |
| 72 | Recent Improvements in Geant4 Electromagnetic Physics Models and Interfaces. <i>Progress in Nuclear Science and Technology</i> , 2011, 2, 898-903.  | 0.3 | 87        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | Interim-PET Scan Interpretation In the Ongoing Prospective Clinical Trial HD 0607, In Advanced-Stage Hodgkin Lymphoma: Results of the the Expert Panel Review. Blood, 2010, 116, 3891-3891.                                     | 1.4 | 0         |
| 74 | Comparative Assessment of Different Criteria for Interim-PET Interpretation in a Cohort of Hodgkin Lymphoma Patients Treated in a Single Center.. Blood, 2009, 114, 3657-3657.  | 1.4 | 0         |
| 75 | Reversible impairment of coronary flow reserve in takotsubo cardiomyopathy: A myocardial PET study. Journal of Nuclear Cardiology, 2008, 15, 811-817.   | 2.1 | 52        |
| 76 | Reversible impairment of coronary flow reserve in takotsubo cardiomyopathy: A myocardial PET study. Journal of Nuclear Cardiology, 2008, 15, 811-817.   | 2.1 | 5         |
| 77 | Virtual MRI-derived SPECT for the visual analysis of Parkinson's disease in early stage. , 2008, , .  |     | 0         |
| 78 | Myocardial scar and insulin resistance predict cardiovascular events in severe ischaemic myocardial dysfunction: a perfusion-metabolism positron emission tomography study. Nuclear Medicine Communications, 2008, 29, 448-454. | 1.1 | 9         |
| 79 | Benchmark of medical dosimetry simulation using the Grid. , 2007, , .   |     | 0         |
| 80 | Evaluation of phase effects in Geant4 microdosimetry models for particle interactions in water. , 2007, , .   |     | 2         |
| 81 | Microdosimetry in high-resolution cellular phantoms using the very low energy electromagnetic extension of the Geant4 toolkit. , 2007, , .  |     | 0         |
| 82 | Correlation between delayed-enhancement magnetic resonance and nitrate myocardial Tc-99m tetrofosmin scintigraphy in myocardial infarction: a case report. Journal of Medical Case Reports, 2007, 1, 120.                       | 0.8 | 2         |
| 83 | Geant4 Physics Processes for Microdosimetry Simulation: Design Foundation and Implementation of the First Set of Models. IEEE Transactions on Nuclear Science, 2007, 54, 2619-2628.   | 2.0 | 86        |
| 84 | Geant4 Model for the Stopping Power of Low Energy Negatively Charged Hadrons. IEEE Transactions on Nuclear Science, 2007, 54, 578-584.  | 2.0 | 6         |
| 85 | Monte Carlo Simulation of Electromagnetic Interactions of Radiation with Liquid Water in the Framework of the Geant4-DNA Project. , 2006, , .   |     | 3         |
| 86 | Atorvastatin Improves Myocardial Perfusion in a Patient With Hypercholesterolemia and Single-Vessel Coronary Disease. Clinical Nuclear Medicine, 2006, 31, 166-167.   | 1.3 | 0         |
| 87 | Reversible inverse mismatch in transient left ventricular apical ballooning: Perfusion/metabolism positron emission tomography imaging. Journal of Nuclear Cardiology, 2006, 13, 587-590.                                       | 2.1 | 22        |
| 88 | Geant4 developments and applications. IEEE Transactions on Nuclear Science, 2006, 53, 270-278.  | 2.0 | 4,869     |
| 89 | Validation of Geant4 Bremsstrahlung models: first results. , 2006, , .  |     | 5         |
| 90 | Geant4 model for the stopping power of low energy negatively charged hadrons. , 2006, , .   |     | 2         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 91 | Models of biological effects of radiation in the Geant4 Toolkit. , 2006, , .  |     | 2         |
| 92 | Breath Control Device with EKG monitoring (ABCDE) for routine imaging and therapy. , 2006, , .  |     | 0         |
| 93 | A powerful simulation tool for medical physics applications: Geant4. Nuclear Physics, Section B, Proceedings Supplements, 2003, 125, 80-84.   | 0.4 | 8         |
| 94 | Monte Carlo dose calculation algorithm on a distributed system. Nuclear Physics, Section B, Proceedings Supplements, 2003, 125, 159-163.  | 0.4 | 3         |
| 95 | Geant4â€™a simulation toolkit. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2003, 506, 250-303. | 1.6 | 17,893    |
| 96 | Feasibility of Intensity-Modulated Radiation Therapy in the Treatment of Advanced Cervical Chordoma. Tumori, 2003, 89, 298-304.   | 1.1 | 11        |
| 97 | Radiomics in Malignant Lymphomas. , 0, , 71-82.   |     | 3         |
| 98 | PET/CT Imaging of Lymphoma Outside the Western World. , 0, , 117-140.   |     | 1         |